Patents by Inventor Jeffrey Edward Dunn

Jeffrey Edward Dunn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Markers for determination of patient responsiveness
    Patent number: 10054588
    Abstract: Compositions and methods are provided for classification of individuals suffering from a demyelinating disease into groups that are informative of the individual's responsiveness or lack of responsiveness to treatment with a J3-interferon (IFNJ3) acting therapy. In particular, it is shown that the effective immunomodulatory treatment of demyelinating disease with IFNJ3 is associated with an increase in circulating transitional B cells in the patient. Diseases of interest include without limitation inflammatory demyelinating diseases of the central nervous system, e.g. multiple sclerosis, neuromyelitis optica (NMO), experimental autoimmune encephalitis (EAE), acute disseminated encephalomyelitis (ADEM), etc.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: August 21, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ryan D. Schubert, Robert C. Axtell, Jeffrey Edward Dunn
  • Markers for Determination of Patient Responsiveness
    Publication number: 20160054320
    Abstract: Compositions and methods are provided for classification of individuals suffering from a demyelinating disease into groups that are informative of the individual's responsiveness or lack of responsiveness to treatment with a J3-interferon (IFNJ3) acting therapy. In particular, it is shown that the effective immunomodulatory treatment of demyelinating disease with IFNJ3 is associated with an increase in circulating transitional B cells in the patient. Diseases of interest include without limitation inflammatory demyelinating diseases of the central nervous system, e.g. multiple sclerosis, neuromyelitis optica (NMO), experimental autoimmune encephalitis (EAE), acute disseminated encephalomyelitis (ADEM), etc.
    Type: Application
    Filed: April 4, 2014
    Publication date: February 25, 2016
    Inventors: Ryan D. Schubert, Robert C. Axtell, Jeffrey Edward Dunn